New Research Affirms U=U | |
 | The PARTNER2 study provides the most definitive data yet that the concept of U=U (undetectable equals untransmittable) is objective truth -- for MSM and heterosexuals alike. |
Getting Real About Long-Acting ART | |
 | Anton Pozniak, M.D., explores a critical question around long-acting antiretrovirals: Once viable options have reached the market, what will be their true impact? |
PrEP: Every Day, or on Demand? | |
 | Interim results from the Prévenir study suggest that, for men who have sex with men, either dosing approach can be successful. |
Dolutegravir and Pregnancy: What's the Risk? | |
 | Lynn Mofenson, M.D., of the Elizabeth Glaser Pediatric AIDS Foundation discusses recent findings on babies born with neural tube defects to women living with HIV. |
An ongoing series to help providers set the foundations of a patient's care.
FDA Approves Doravirine (Pifeltro) and New FDC With TDF/3TC (Delstrigo) in the U.S.
More People With HIV Virally Suppressed on Doravirine Than Darunavir at 96 Weeks, Study Shows
Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices -- but Really 2 Are Best
Who Tends to Gain Weight With HIV Treatment?
The field of hepatitis C disease management is in the midst of dramatic change. This series provides overviews, research updates, and more.
Which Hepatitis C Treatment to Start
Prison Health Is Public Health: The Case for Testing and Treating Hepatitis C in Prisons
Too Few Teens and Youth Adults Using Opioids Are Screened for Hepatitis C and HIV, New Study Finds
This Week in HIV Research: This Is Your Brain on Stigma
Optimizing HIV and Hepatitis C Continuum of Care Outcomes for Criminal Justice-Involved Populations
Gay Men Who Use Crystal Meth Need Integrated Care
Can PrEP on Demand for HIV Prevention Work in the U.S.? Experts Answer Your Questions
Italian Study Explores Dual Drug Regimens as Maintenance Treatment
Getting Clergy to Step Out on Faith With HIV Education and Mobilization
Combinations of Super Antibodies May Keep HIV at Bay
This Week in HIV Research: Let's Get Real About Treatment Efficacy
Ketogenic Diet May Hold Promise for Older People With HIV
Why Nurses Should Take the HIV Self-Test
Meeting the Challenge of Engaging Men in HIV Prevention and Treatment
Not All People Are Equally Vulnerable to Hepatitis C -- New Study
New Dangers Emerge as Cocaine, Meth, and Other Stimulants Overtake Opioids
AIDS Treatment Has Progressed, but Without a Vaccine, Suffering Still Abounds
This Week in HIV Research: Transgender Women in the Spotlight
Post-AIDS 2018 Updates on HIV Cure Research
Video SNiP: PET Scan "Hot Spots" Help Visualize Inflammatory Complication of HIV
This Week in HIV Research: Many Black MSM on PrEP Are Already Positive
HIV-Negative Black Gay Men: Two Recent Studies Show Some Factors That Help Them to Remain So
What's Really Behind the Recent Decline in U.S. Hepatitis C Prevalence?
Why HIV Care Providers Should Discuss Marijuana Use With Their Patients
This Week in HIV Research: How Should We Measure Success?
PrEP Is Safe for Pregnant Women Who Want the HIV Prevention Drug, a New Study Finds
© 2018 Remedy Health Media, LLC. All Rights Reserved
TheBodyPRO: About TheBodyPRO | Contact TheBodyPRO | Content Policy | Advertise With Us
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
TheBodyPRO is a service of Remedy Health Media, 461 Fifth Avenue, 14th Floor, New York, NY 10017. TheBodyPRO and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
